Online citations, reference lists, and bibliographies.
← Back to Search

A Personal Retrospective: Elevating Anandamide (AEA) By Targeting Fatty Acid Amide Hydrolase (FAAH) And The Fatty Acid Binding Proteins (FABPs)

D. Deutsch
Published 2016 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This perspective was adapted from a Career Achievement Award talk given at the International Cannabinoid Research Society Symposium in Bukovina, Poland on June 27, 2016. As a biochemist working in the neurosciences, I was always fascinated with neurotransmitter inactivation. In 1993 we identified an enzyme activity that breaks down anandamide. We called the enzyme anandamide amidase, now called FAAH. We and other laboratories developed FAAH inhibitors that were useful reagents that also proved to have beneficial physiological effects and until recently, new generations of inhibitors were in clinical trials. Nearly all neurotransmitters are water soluble and as such, require a transmembrane protein transporter to pass through the lipid membrane for inactivation inside the cell. However, using model systems, we and others have shown that this is unnecessary for anandamide, an uncharged hydrophobic molecule that readily diffuses across the cellular membrane. Interestingly, its uptake is driven by the concentration gradient resulting from its breakdown mainly by FAAH localized in the endoplasmic reticulum. We identified the FABPs as intracellular carriers that “solubilize” anandamide, transporting anandamide to FAAH. Compounds that bind to FABPs block AEA breakdown, raising its level. The cannabinoids (THC and CBD) also were discovered to bind FABPs and this may be one of the mechanisms by which CBD works in childhood epilepsy, raising anandamide levels. Targeting FABPs may be advantageous since they have some tissue specificity and do not require reactive serine hydrolase inhibitors, as does FAAH, with potential for off-target reactions. At the International Cannabis Research Society Symposium in 1992, Raphe Mechoulam revealed that his laboratory isolated an endogenous lipid molecule that binds to the CB1 receptor (cannabinoid receptor type 1) and this became the milestone paper published in December of that year describing anandamide (AEA, Devane et al., 1992). As to be expected, this discovery raised the issues of AEA's synthesis and breakdown.
This paper references
10.1016/j.phrs.2014.04.001
New players in the fatty acyl ethanolamide metabolism.
Iffat Ara Sonia Rahman (2014)
10.1016/j.euroneuro.2015.02.005
The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs—A practical view
C. Fowler (2015)
10.1074/jbc.M003161200
The Cellular Uptake of Anandamide Is Coupled to Its Breakdown by Fatty-acid Amide Hydrolase*
D. Deutsch (2001)
10.1021/JA062999H
The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases.
J. Alexander (2006)
10.1007/s11745-016-4155-8
Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias
F. Schroeder (2016)
10.1021/BI990637Z
Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties.
M. Patricelli (1999)
10.1126/SCIENCE.1076535
Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling
M. Bracey (2002)
Evidence against the presence
Deutsch (2003)
10.1016/S0960-894X(98)00734-3
Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition.
D. Boger (1999)
10.1371/journal.pone.0004989
The Insertion and Transport of Anandamide in Synthetic Lipid Membranes Are Both Cholesterol-Dependent
E. Di Pasquale (2009)
10.1073/pnas.0901515106
Identification of intracellular carriers for the endocannabinoid anandamide
M. Kaczocha (2009)
10.1016/j.pain.2012.04.020
An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee
J. P. Huggins (2012)
Enzymatic synthesis and degradation
Anandamide Uptake (1993)
This is an Open Access article distribut...
(2007)
10.1038/384083A0
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
B. Cravatt (1996)
10.1016/S0140-6736(16)30661-4
New report on drug trial disaster in France
B. Casassus (2016)
10.1038/nn.2986
A catalytically silent FAAH-1 variant drives anandamide transport in neurons
J. Fu (2012)
10.1006/BBRC.1997.6072
Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
D. Deutsch (1997)
10.1016/0014-2999(94)00618-H
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations.
R. Pertwee (1995)
The movement of N
C. J. Hillard (2000)
10.1016/j.bbalip.2011.07.009
Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways.
K. Tsuboi (2011)
10.1039/c000237b
Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo.
G. Simon (2010)
10.1016/bs.vh.2014.12.011
Endocannabinoid transport revisited.
S. Nicolussi (2015)
Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells.
F. Rakhshan (2000)
10.1073/pnas.0806121105
Structure-guided inhibitor design for human FAAH by interspecies active site conversion
Mauro Mileni (2008)
10.1073/PNAS.91.14.6698
Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes.
W. Devane (1994)
10.1007/s13311-015-0377-3
Molecular Targets of Cannabidiol in Neurological Disorders
Clementino Ibeas Bih (2015)
10.1037/e495572006-007
Inhibitors of anandamide breakdown.
D. Deutsch (1997)
Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1
(2016)
10.3109/14756366.2011.643304
Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide
C. Fowler (2013)
10.1124/MOL.59.6.1369
Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide.
T. Day (2001)
10.1016/J.LFS.2005.05.007
Anandamide transport: a critical review.
S. Glaser (2005)
10.1016/j.pharmthera.2004.07.008
Anandamide transport.
M. J. McFarland (2004)
Endocannabinoid transport revisited. Vitam
S. 89108 Nicolussi (2015)
Identification of two serine
R. L. Omeir (1999)
10.2165/00128413-200816540-00020
Tanezumab takes on pain due to osteoarthritis of the knee
(2008)
Effects of anandamide
S. R. Childers (1994)
Enzymatic synthesis of anandamide
W. A. Devane (1994)
Carriermediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells
F Rakhshan (2000)
10.1111/j.1476-5381.2011.01364.x
Endocannabinoid tone versus constitutive activity of cannabinoid receptors
A. Howlett (2011)
10.1517/13543776.2015.1067683
Fatty acid amide hydrolase inhibitors: a patent review (2009 – 2014)
A. Lodola (2015)
10.2174/187152711796234989
Fatty acid amide hydrolase inhibitors--progress and potential.
I. Khanna (2011)
10.1007/978-3-319-20825-1_4
The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.
C. Fowler (2015)
Unique pathway for anandamide synthesis
A. A. Izzo (2011)
10.1038/nbt826
Discovering potent and selective reversible inhibitors of enzymes in complex proteomes
D. Leung (2003)
10.1016/j.bbalip.2016.03.003
Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain.
E. Leishman (2016)
10.1016/j.neuropharm.2011.10.011
Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride
R. Vann (2012)
10.1016/j.neuropharm.2007.05.020
Multiple pathways involved in the biosynthesis of anandamide
J. Liu (2008)
10.1038/nrd2589
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
M. Furuhashi (2008)
10.1016/j.phrs.2013.12.010
Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.
S. Nicolussi (2014)
Role of fatty acid
T. A. Day (2001)
Anandamide transport: a critical review The movement of Narachidonoylethanolamine (anandamide) across cellular membranes
S T Glaser (2000)
10.1006/BBRC.1997.6000
Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase.
L. De Petrocellis (1997)
10.1146/ANNUREV.BIOCHEM.74.082803.133450
Structure and function of fatty acid amide hydrolase.
M. K. McKinney (2005)
10.1038/084538a0
Structure and Function.
H. Kowarzyk (1910)
10.1016/j.neuropharm.2004.12.012
Accumulation of anandamide: Evidence for cellular diversity
C. Hillard (2005)
10.1194/jlr.M500411-JLR200
Effect of an unstirred layer on the membrane permeability of anandamide Published, JLR Papers in Press, December 19, 2005.
I. Bojesen (2006)
10.1038/372686A0
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
V. Marzo (1994)
Arachidonoyl ethanolamide - as a substrate for anandamide amidase
R. L. Omeir (1995)
Endocannabinoid tone versus constitutive activity
D. G. Deutsch (2011)
10.1073/PNAS.0400997101
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.
D. Fegley (2004)
10.1016/s0021-9258(18)96775-x
Microsomal synthesis of fatty acid amides.
N. Bachur (1966)
10.1111/febs.12212
Transport of endocannabinoids across the plasma membrane and within the cell
C. Fowler (2013)
10.1073/pnas.1017689108
Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver
B. Mukhopadhyay (2011)
10.1371/journal.pone.0079355
Role of FAAH-Like Anandamide Transporter in Anandamide Inactivation
KwanNok Leung (2013)
10.1021/cn300001w
Anandamide externally added to lipid vesicles containing trapped fatty acid amide hydrolase (FAAH) is readily hydrolyzed in a sterol-modulated fashion.
M. Kaczocha (2012)
cannabinoid receptor
V. DiMarzo (1946)
10.1016/S0304-3940(97)00673-3
The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine
G. Arreaza (1997)
10.1016/0006-2952(94)90134-1
Effects of anandamide on cannabinoid receptors in rat brain membranes.
S. Childers (1994)
10.1016/J.EJPHAR.2004.03.048
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle.
C. Fowler (2004)
10.1073/pnas.0730816100
Evidence against the presence of an anandamide transporter
S. Glaser (2003)
10.1371/journal.pone.0103479
Involvement of Fatty Acid Amide Hydrolase and Fatty Acid Binding Protein 5 in the Uptake of Anandamide by Cell Lines with Different Levels of Fatty Acid Amide Hydrolase Expression: A Pharmacological Study
E. Björklund (2014)
10.1126/SCIENCE.1470919
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
W. Devane (1992)
Ibuprofen inhibits rat brain
G. Tiger (1997)
10.1016/0024-3205(95)00181-5
Arachidonoyl ethanolamide-[1,2-14C] as a substrate for anandamide amidase.
R. Omeir (1995)
10.1016/s0021-9258(17)44667-9
Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type.
P. Schmid (1983)
10.1073/pnas.1103566108
Unique pathway for anandamide synthesis and liver regeneration
A. Izzo (2011)
10.1016/S0009-3084(00)00190-0
The fatty acid amide hydrolase (FAAH).
D. Deutsch (2002)
Chemical and mutagenic
M. P. Patricelli (1999)
Characterization of mice
G. M. Simon (2010)
Fatty acid amide hydrolase inhibitors
C. W. Alexander (2011)
10.1371/journal.pone.0010239
Exploiting Nanotechnologies and TRPV1 Channels to Investigate the Putative Anandamide Membrane Transporter
A. Ligresti (2010)
Fatty acid amide hydrolase
A. Lodola (2015)
Fatty acid amide hydrolase inhibitors: a patent review
A Lodola (2009)
Exploiting nanotechnologies and TRPV1
Moriello (2010)
10.1016/j.tips.2013.12.003
Has FLAT fallen flat?
C. Fowler (2014)
10.1038/tp.2012.15
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. Leweke (2012)
10.1074/jbc.M114.618447
Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)*
Matthew W. Elmes (2015)
10.1016/S0006-2952(96)00830-1
Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase.
D. Deutsch (1997)
10.1371/journal.pone.0050968
Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs
William T. Berger (2012)
10.1016/s0021-9258(17)38695-7
Properties of rat liver N-acylethanolamine amidohydrolase.
P. Schmid (1985)
Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship.
C. Fowler (1997)
10.1107/S1399004713026795
Crystallographic study of FABP5 as an intracellular endocannabinoid transporter.
B. Sanson (2014)
10.1074/jbc.M111.304907
Fatty Acid-binding Proteins Transport N-Acylethanolamines to Nuclear Receptors and Are Targets of Endocannabinoid Transport Inhibitors*
M. Kaczocha (2011)
10.1016/J.LFS.2005.05.018
N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: a novel enzyme of the beta-lactamase fold family releasing anandamide and other N-acylethanolamines.
N. Ueda (2005)
Inhibitors of arachidonoyl ethanolamide hydrolysis.
B. Koutek (1994)
10.1006/BBRC.1999.1524
Identification of two serine residues involved in catalysis by fatty acid amide hydrolase.
R. Omeir (1999)
10.1016/S0009-3084(00)00191-2
The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes.
C. Hillard (2000)
10.1016/0006-2952(93)90486-G
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.
D. Deutsch (1993)
10.1021/JM020818Q
Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
M. van der Stelt (2002)
10.1194/JLR.M400498-JLR200
Membrane transport of anandamide through resealed human red blood cell membranes Published, JLR Papers in Press, June 1, 2005. DOI 10.1194/jlr.M400498-JLR200
I. Bojesen (2005)
Cannabinoid properties of methylfluorophosphonate analogs.
B. Martin (2000)
Membrane transport of anandamide
I. N. Bojesen (2005)
Oxygenated metabolites of anandamide
Veldink (2002)
Biochem. Pharmacol



This paper is referenced by
10.1007/s40263-019-00664-w
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
E. Galaj (2019)
10.1002/lipd.12192
Sterol Carrier Protein-2/Sterol Carrier Protein-x/Fatty Acid Binding Protein-1 Ablation Impacts Response of Brain Endocannabinoid to High-Fat Diet.
G. Martin (2019)
10.1007/s00482-018-0299-1
Cannabinoide in der Schmerzmedizin
M. Karst (2018)
10.1016/j.neures.2017.04.019
N-stearoyltyrosine protects primary cortical neurons against oxygen-glucose deprivation-induced apoptosis through inhibiting anandamide inactivation system
Heng-Jing Cui (2017)
10.1089/can.2017.0014
Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults
D. Arndt (2017)
10.3389/fphar.2019.00627
Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain
J. De Ternay (2019)
10.1016/j.neuropharm.2020.108241
Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents
C. Jordan (2020)
10.1002/9780470015902.A0027093
Endocannabinoid System: An Update
N. Battista (2017)
10.1080/03602532.2018.1428344
Targeting the endocannabinoid system as a potential anticancer approach
Rico Schwarz (2018)
10.1513/AnnalsATS.201908-581PS
The Cannabis Conundrum: Look Both Ways before Crossing a Deserted Road.
Theodore J. Witek (2019)
10.3390/ijms21176235
Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
T. Behl (2020)
10.13130/MICELI-MATTEO_PHD2018-12-11
REGULATING HYDROLASES OF THE ENDOCANNABINOID SYSTEM: NOVEL PHOTOMETRIC ASSAYS FOR DRUG DISCOVERY
M. Miceli (2018)
10.1016/j.ejmech.2018.04.050
SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
S. Yan (2018)
10.1002/lipd.12071
Impact of Fabp1 Gene Ablation on Uptake and Degradation of Endocannabinoids in Mouse Hepatocytes.
A. McIntosh (2018)
10.1371/journal.pone.0212039
miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia—Effect of cannabinoids
A. Juknat (2019)
10.1111/bph.14769
Opioid‐sparing effects of cannabinoids on morphine analgesia: participation of CB1 and CB2 receptors
Xiaohong Chen (2019)
10.1016/j.lfs.2018.04.054
Enhanced endocannabinoid tone as a potential target of pharmacotherapy
M. Toczek (2018)
10.1002/pro.3875
Two fatty acid‐binding proteins expressed in the intestine interact differently with endocannabinoids
May Poh Lai (2020)
10.1111/bph.14780
Distinct functions of endogenous cannabinoid system in alcohol abuse disorders
B. S. Basavarajappa (2019)
10.1101/815654
Heritability and family-based GWAS analyses of the N-acyl ethanolamine and ceramide plasma lipidome
K. McGurk (2020)
10.1039/c9cp05704h
Molecular mechanism with regard to the binding selectivity of inhibitors toward FABP5 and FABP7 explored by multiple short molecular dynamics simulations and free energy analyses.
Jianzhong Chen (2020)
10.1016/j.lfs.2020.118109
The endocannabinoid signaling pathway as an emerging target in pharmacotherapy, earmarking mitigation of destructive events in rheumatoid arthritis.
Ishnoor Kaur (2020)
10.1111/acer.14256
Cannabinoids and the Microbiota-Gut-Brain-Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders.
Hollis C Karoly (2019)
10.3389/fnmol.2017.00166
Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years
M. Maccarrone (2017)
10.1016/bs.mie.2017.06.024
Lipidomics: A Corrective Lens for Enzyme Myopia.
H. Bradshaw (2017)
10.1016/j.neuropharm.2019.107740
Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms
E. Galaj (2019)
10.1021/acs.biochem.7b00194
The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites.
Hao-Chi Hsu (2017)
10.1016/j.ejmech.2019.111953
A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents.
R. K. P. Tripathi (2019)
10.1016/j.bbalip.2017.08.006
Mammalian enzymes responsible for the biosynthesis of N-acylethanolamines.
Z. Hussain (2017)
Semantic Scholar Logo Some data provided by SemanticScholar